MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved new REAL-Time Continuous Glucose Monitoring (CGM) devices for children and teenagers ages 7-17. Previously approved for only adult patients, Medtronic’s REAL-Time CGM will soon be available in specifically designed pediatric models of the MiniMed Paradigm® REAL-Time System and Guardian® REAL-Time System.
